Biotech Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Private, Subsidiary
- Established
- 2000-08-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.biotechplc.com
A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
Phase 4
Active, not recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: cis-platinumRadiation: IMRT combine with cisplatin concurrent chemotherapyDrug: painkiller
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 171
- Registration Number
- NCT06879691
- Locations
- 🇨🇳
Baotou Cancer Hospital, Baotou, Inner Mongolia, China
Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma
Phase 3
Completed
- Conditions
- Cervical Squamous Cell CarcinomaPersistent
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT06781073
- Locations
- 🇨🇳
Cancer Institute and Hospital , Chinese Academy of Medical Sciences, Beijing, China
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Pancreatic Cancer, Adult
- Interventions
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06781086
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
A Phase I Clinical Trial of JH013 Injection
Phase 1
Not yet recruiting
- Conditions
- Healthy Subjects (HS)
- Interventions
- Drug: JH013 injectionDrug: Placebo
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06633055
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
Phase 3
Not yet recruiting
- Conditions
- Refractory Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT06343116
A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma
Phase 3
Not yet recruiting
- Conditions
- Cervical Cancer
- Interventions
- Biological: NimotuzumabRadiation: External Beam Radiotherapy (EBRT)Radiation: Brachytherapy
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06333821
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT05986162
Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Gastric or Esophagogastric Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 354
- Registration Number
- NCT05978050
- Locations
- 🇨🇳
National Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Safety and Preliminary Clinical Activity of Itolizumab in ARDS
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05978544
Safety and Clinical Activity of Itolizumab in aGVHD
Phase 1
Recruiting
- Conditions
- Acute Graft Versus Host Disease
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT05823675
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath